Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease
The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of...
Gespeichert in:
| Veröffentlicht in: | International journal of molecular sciences 2019-12, Vol.21 (1), p.70 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | 70 |
| container_title | International journal of molecular sciences |
| container_volume | 21 |
| creator | Sánchez-Campillo, María Ruiz-Pastor, María José Gázquez, Antonio Marín-Muñoz, Juan Noguera-Perea, Fuensanta Ruiz-Alcaraz, Antonio J Manzanares-Sánchez, Salvadora Antúnez, Carmen Larqué, Elvira |
| description | The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD. Three groups were established: 38 healthy controls, 48 subjects with moderate AD (GDS4), and 47 with severe AD (GDS6). We analyzed postmortem brain samples from the hippocampus of 11 healthy controls and 11 severe AD patients. Fatty acid (FA) was determined in serum and brain by gas chromatography. Blood and brain MFSD2a protein expression was analyzed by Western blotting. We found a significant and progressive decline of MFSD2a levels in blood of AD patients (Control 0.83 ± 0.13, GDS4 0.72 ± 0.09, GDS6 0.48 ± 0.05*,
˂ 0.01). We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD. No differences were found in MFSD2a expression or FA levels in brain of controls and AD subjects. MFSD2A carrier was analyzed in AD patients for the first time and the level of MFSD2a in the whole blood could be a potential biomarker of this disease. |
| doi_str_mv | 10.3390/ijms21010070 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981746</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2548679679</sourcerecordid><originalsourceid>FETCH-LOGICAL-c412t-931320e404bd1839ec0e2558f7eadedb5cfa08401347cea065d34133beef856e3</originalsourceid><addsrcrecordid>eNpdkctLAzEQxoMotj5uniXgQQ-uTh77ugjV-oKKgnoO2d1Zm7rb1KQr6F9vilqqMDAD8-Pjm_kI2WNwIkQOp2bSes6AAaSwRvpMch4BJOn6ytwjW95PALjgcb5JeoJlSai4T-6HWDrUHit63lhb0RG-Y0NtTe-uHodcU-2ppg92jtO50Q09N7bV7hXdAhk0n2M0LbpDT4fGL2R2yEatG4-7P32bPF9dPl3cRKP769uLwSgqJePzKBdMcEAJsqhYJnIsAXkcZ3WKusKqiMtaQyaBCZmWqCGJKyGZEAVincUJim1y9q0764oWqzLYc7pRM2eCvQ9ltVF_N1MzVi_2XSV5xlKZBIGjHwFn3zr0c9UaX2LT6CnazqvwqjwVwVIW0IN_6MR2bhrOUzyWWZLmoQJ1_E2VznrvsF6aYaAWSanVpAK-v3rAEv6NRnwB9QCN3A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2548679679</pqid></control><display><type>article</type><title>Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease</title><source>PubMed (Medline)</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Sánchez-Campillo, María ; Ruiz-Pastor, María José ; Gázquez, Antonio ; Marín-Muñoz, Juan ; Noguera-Perea, Fuensanta ; Ruiz-Alcaraz, Antonio J ; Manzanares-Sánchez, Salvadora ; Antúnez, Carmen ; Larqué, Elvira</creator><creatorcontrib>Sánchez-Campillo, María ; Ruiz-Pastor, María José ; Gázquez, Antonio ; Marín-Muñoz, Juan ; Noguera-Perea, Fuensanta ; Ruiz-Alcaraz, Antonio J ; Manzanares-Sánchez, Salvadora ; Antúnez, Carmen ; Larqué, Elvira</creatorcontrib><description>The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD. Three groups were established: 38 healthy controls, 48 subjects with moderate AD (GDS4), and 47 with severe AD (GDS6). We analyzed postmortem brain samples from the hippocampus of 11 healthy controls and 11 severe AD patients. Fatty acid (FA) was determined in serum and brain by gas chromatography. Blood and brain MFSD2a protein expression was analyzed by Western blotting. We found a significant and progressive decline of MFSD2a levels in blood of AD patients (Control 0.83 ± 0.13, GDS4 0.72 ± 0.09, GDS6 0.48 ± 0.05*,
˂ 0.01). We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD. No differences were found in MFSD2a expression or FA levels in brain of controls and AD subjects. MFSD2A carrier was analyzed in AD patients for the first time and the level of MFSD2a in the whole blood could be a potential biomarker of this disease.</description><identifier>ISSN: 1422-0067</identifier><identifier>ISSN: 1661-6596</identifier><identifier>EISSN: 1422-0067</identifier><identifier>DOI: 10.3390/ijms21010070</identifier><identifier>PMID: 31861865</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Aged ; Alzheimer Disease - blood ; Alzheimer Disease - pathology ; Alzheimer's disease ; Biomarkers ; Biomarkers - analysis ; Biomarkers - blood ; Blood ; Brain - pathology ; Dementia ; Diabetes ; Docosahexaenoic acid ; Fatty acids ; Fatty Acids - blood ; Female ; Fish oils ; Gas chromatography ; Humans ; Hypertension ; Lipids ; Male ; Microcephaly ; Neurodegeneration ; Protein expression ; Proteins ; Symporters - analysis ; Symporters - blood ; Western blotting</subject><ispartof>International journal of molecular sciences, 2019-12, Vol.21 (1), p.70</ispartof><rights>2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2019 by the authors. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c412t-931320e404bd1839ec0e2558f7eadedb5cfa08401347cea065d34133beef856e3</citedby><cites>FETCH-LOGICAL-c412t-931320e404bd1839ec0e2558f7eadedb5cfa08401347cea065d34133beef856e3</cites><orcidid>0000-0002-7177-8341 ; 0000-0003-4222-7038 ; 0000-0001-6913-0610 ; 0000-0001-5023-7442</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981746/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981746/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31861865$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Sánchez-Campillo, María</creatorcontrib><creatorcontrib>Ruiz-Pastor, María José</creatorcontrib><creatorcontrib>Gázquez, Antonio</creatorcontrib><creatorcontrib>Marín-Muñoz, Juan</creatorcontrib><creatorcontrib>Noguera-Perea, Fuensanta</creatorcontrib><creatorcontrib>Ruiz-Alcaraz, Antonio J</creatorcontrib><creatorcontrib>Manzanares-Sánchez, Salvadora</creatorcontrib><creatorcontrib>Antúnez, Carmen</creatorcontrib><creatorcontrib>Larqué, Elvira</creatorcontrib><title>Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease</title><title>International journal of molecular sciences</title><addtitle>Int J Mol Sci</addtitle><description>The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD. Three groups were established: 38 healthy controls, 48 subjects with moderate AD (GDS4), and 47 with severe AD (GDS6). We analyzed postmortem brain samples from the hippocampus of 11 healthy controls and 11 severe AD patients. Fatty acid (FA) was determined in serum and brain by gas chromatography. Blood and brain MFSD2a protein expression was analyzed by Western blotting. We found a significant and progressive decline of MFSD2a levels in blood of AD patients (Control 0.83 ± 0.13, GDS4 0.72 ± 0.09, GDS6 0.48 ± 0.05*,
˂ 0.01). We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD. No differences were found in MFSD2a expression or FA levels in brain of controls and AD subjects. MFSD2A carrier was analyzed in AD patients for the first time and the level of MFSD2a in the whole blood could be a potential biomarker of this disease.</description><subject>Aged</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - pathology</subject><subject>Alzheimer's disease</subject><subject>Biomarkers</subject><subject>Biomarkers - analysis</subject><subject>Biomarkers - blood</subject><subject>Blood</subject><subject>Brain - pathology</subject><subject>Dementia</subject><subject>Diabetes</subject><subject>Docosahexaenoic acid</subject><subject>Fatty acids</subject><subject>Fatty Acids - blood</subject><subject>Female</subject><subject>Fish oils</subject><subject>Gas chromatography</subject><subject>Humans</subject><subject>Hypertension</subject><subject>Lipids</subject><subject>Male</subject><subject>Microcephaly</subject><subject>Neurodegeneration</subject><subject>Protein expression</subject><subject>Proteins</subject><subject>Symporters - analysis</subject><subject>Symporters - blood</subject><subject>Western blotting</subject><issn>1422-0067</issn><issn>1661-6596</issn><issn>1422-0067</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpdkctLAzEQxoMotj5uniXgQQ-uTh77ugjV-oKKgnoO2d1Zm7rb1KQr6F9vilqqMDAD8-Pjm_kI2WNwIkQOp2bSes6AAaSwRvpMch4BJOn6ytwjW95PALjgcb5JeoJlSai4T-6HWDrUHit63lhb0RG-Y0NtTe-uHodcU-2ppg92jtO50Q09N7bV7hXdAhk0n2M0LbpDT4fGL2R2yEatG4-7P32bPF9dPl3cRKP769uLwSgqJePzKBdMcEAJsqhYJnIsAXkcZ3WKusKqiMtaQyaBCZmWqCGJKyGZEAVincUJim1y9q0764oWqzLYc7pRM2eCvQ9ltVF_N1MzVi_2XSV5xlKZBIGjHwFn3zr0c9UaX2LT6CnazqvwqjwVwVIW0IN_6MR2bhrOUzyWWZLmoQJ1_E2VznrvsF6aYaAWSanVpAK-v3rAEv6NRnwB9QCN3A</recordid><startdate>20191220</startdate><enddate>20191220</enddate><creator>Sánchez-Campillo, María</creator><creator>Ruiz-Pastor, María José</creator><creator>Gázquez, Antonio</creator><creator>Marín-Muñoz, Juan</creator><creator>Noguera-Perea, Fuensanta</creator><creator>Ruiz-Alcaraz, Antonio J</creator><creator>Manzanares-Sánchez, Salvadora</creator><creator>Antúnez, Carmen</creator><creator>Larqué, Elvira</creator><general>MDPI AG</general><general>MDPI</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-7177-8341</orcidid><orcidid>https://orcid.org/0000-0003-4222-7038</orcidid><orcidid>https://orcid.org/0000-0001-6913-0610</orcidid><orcidid>https://orcid.org/0000-0001-5023-7442</orcidid></search><sort><creationdate>20191220</creationdate><title>Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease</title><author>Sánchez-Campillo, María ; Ruiz-Pastor, María José ; Gázquez, Antonio ; Marín-Muñoz, Juan ; Noguera-Perea, Fuensanta ; Ruiz-Alcaraz, Antonio J ; Manzanares-Sánchez, Salvadora ; Antúnez, Carmen ; Larqué, Elvira</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c412t-931320e404bd1839ec0e2558f7eadedb5cfa08401347cea065d34133beef856e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - pathology</topic><topic>Alzheimer's disease</topic><topic>Biomarkers</topic><topic>Biomarkers - analysis</topic><topic>Biomarkers - blood</topic><topic>Blood</topic><topic>Brain - pathology</topic><topic>Dementia</topic><topic>Diabetes</topic><topic>Docosahexaenoic acid</topic><topic>Fatty acids</topic><topic>Fatty Acids - blood</topic><topic>Female</topic><topic>Fish oils</topic><topic>Gas chromatography</topic><topic>Humans</topic><topic>Hypertension</topic><topic>Lipids</topic><topic>Male</topic><topic>Microcephaly</topic><topic>Neurodegeneration</topic><topic>Protein expression</topic><topic>Proteins</topic><topic>Symporters - analysis</topic><topic>Symporters - blood</topic><topic>Western blotting</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Sánchez-Campillo, María</creatorcontrib><creatorcontrib>Ruiz-Pastor, María José</creatorcontrib><creatorcontrib>Gázquez, Antonio</creatorcontrib><creatorcontrib>Marín-Muñoz, Juan</creatorcontrib><creatorcontrib>Noguera-Perea, Fuensanta</creatorcontrib><creatorcontrib>Ruiz-Alcaraz, Antonio J</creatorcontrib><creatorcontrib>Manzanares-Sánchez, Salvadora</creatorcontrib><creatorcontrib>Antúnez, Carmen</creatorcontrib><creatorcontrib>Larqué, Elvira</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of molecular sciences</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Sánchez-Campillo, María</au><au>Ruiz-Pastor, María José</au><au>Gázquez, Antonio</au><au>Marín-Muñoz, Juan</au><au>Noguera-Perea, Fuensanta</au><au>Ruiz-Alcaraz, Antonio J</au><au>Manzanares-Sánchez, Salvadora</au><au>Antúnez, Carmen</au><au>Larqué, Elvira</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease</atitle><jtitle>International journal of molecular sciences</jtitle><addtitle>Int J Mol Sci</addtitle><date>2019-12-20</date><risdate>2019</risdate><volume>21</volume><issue>1</issue><spage>70</spage><pages>70-</pages><issn>1422-0067</issn><issn>1661-6596</issn><eissn>1422-0067</eissn><abstract>The protein Major Facilitator Superfamily Domain containing 2A (MFSD2a) was recently described as the primary carrier for docosahexaenoic acid (DHA) into the brain. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by lower DHA levels in blood lipids. The aim of this study was to investigate the expression of MFSD2a in the whole blood and brain as a potential biomarker of AD. Three groups were established: 38 healthy controls, 48 subjects with moderate AD (GDS4), and 47 with severe AD (GDS6). We analyzed postmortem brain samples from the hippocampus of 11 healthy controls and 11 severe AD patients. Fatty acid (FA) was determined in serum and brain by gas chromatography. Blood and brain MFSD2a protein expression was analyzed by Western blotting. We found a significant and progressive decline of MFSD2a levels in blood of AD patients (Control 0.83 ± 0.13, GDS4 0.72 ± 0.09, GDS6 0.48 ± 0.05*,
˂ 0.01). We also corroborated a significant reduction of DHA and other n-3 long-chain polyunsaturated FA in serum of AD. No differences were found in MFSD2a expression or FA levels in brain of controls and AD subjects. MFSD2A carrier was analyzed in AD patients for the first time and the level of MFSD2a in the whole blood could be a potential biomarker of this disease.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>31861865</pmid><doi>10.3390/ijms21010070</doi><orcidid>https://orcid.org/0000-0002-7177-8341</orcidid><orcidid>https://orcid.org/0000-0003-4222-7038</orcidid><orcidid>https://orcid.org/0000-0001-6913-0610</orcidid><orcidid>https://orcid.org/0000-0001-5023-7442</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1422-0067 |
| ispartof | International journal of molecular sciences, 2019-12, Vol.21 (1), p.70 |
| issn | 1422-0067 1661-6596 1422-0067 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6981746 |
| source | PubMed (Medline); MDPI - Multidisciplinary Digital Publishing Institute; MEDLINE; EZB Electronic Journals Library |
| subjects | Aged Alzheimer Disease - blood Alzheimer Disease - pathology Alzheimer's disease Biomarkers Biomarkers - analysis Biomarkers - blood Blood Brain - pathology Dementia Diabetes Docosahexaenoic acid Fatty acids Fatty Acids - blood Female Fish oils Gas chromatography Humans Hypertension Lipids Male Microcephaly Neurodegeneration Protein expression Proteins Symporters - analysis Symporters - blood Western blotting |
| title | Decreased Blood Level of MFSD2a as a Potential Biomarker of Alzheimer's Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T16%3A38%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20Blood%20Level%20of%20MFSD2a%20as%20a%20Potential%20Biomarker%20of%20Alzheimer's%20Disease&rft.jtitle=International%20journal%20of%20molecular%20sciences&rft.au=S%C3%A1nchez-Campillo,%20Mar%C3%ADa&rft.date=2019-12-20&rft.volume=21&rft.issue=1&rft.spage=70&rft.pages=70-&rft.issn=1422-0067&rft.eissn=1422-0067&rft_id=info:doi/10.3390/ijms21010070&rft_dat=%3Cproquest_pubme%3E2548679679%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2548679679&rft_id=info:pmid/31861865&rfr_iscdi=true |